Concord Biotech Ltd
NSE:CONCORDBIO
Operating Margin
Concord Biotech Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
C
|
Concord Biotech Ltd
NSE:CONCORDBIO
|
160.6B INR |
36%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
677.8B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
367.1B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
207.7B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
183.1B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
162.5B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
195.9B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
117B EUR |
22%
|
Concord Biotech Ltd
Glance View
Nestled in the vibrant landscape of the Indian pharmaceutical industry, Concord Biotech Ltd. has woven itself into the intricate fabric of global healthcare solutions. Founded in 2000, the company has carved a niche for itself by becoming a leading manufacturer of fermentation-based biopharmaceutical APIs (Active Pharmaceutical Ingredients). Its core strength lies in developing recombinant APIs and fermentation-based life-saving drugs, establishing a robust pipeline that caters to the therapeutic needs of oncology, immunology, and infectious diseases. Concord Biotech's state-of-the-art manufacturing facilities adhere to stringent international standards, including approvals from USFDA and EUGMP, enabling the company to establish a significant presence in markets across the globe. The company's revenue model thrives on the optimized production of high-demand biotech APIs, synergizing innovation with commercial viability. By partnering with global pharmaceutical giants, Concord Biotech boosts the formulation and development of finished dosage forms, leveraging its cutting-edge research and development capabilities. The firm taps into economies of scale via partnerships and strategic alliances, which allow it to competitively price its offerings while maintaining robust profit margins. Moreover, the company continually invests in expanding its product portfolio and production capacities, ensuring sustainable growth and a strong market position in the ever-evolving pharmaceutical landscape. Through a combination of technological prowess and market insight, Concord Biotech Ltd. paves its path as a cornerstone in the global pharmaceutical supply chain.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Concord Biotech Ltd's most recent financial statements, the company has Operating Margin of 36.4%.
You don't have any saved screeners yet